Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue SUPPL.2, 2011, Pages 4-12

  Mok, Tony S K ^a   Hsia, Te Chun ^g   Tsai, Chun Ming ^h   Tsang, Kenneth ^b,c   Chang, Gee Chen ⁱ   Chang, John Wen Cheng ^j   Thitiya, Sirisinha ^d   Sriuranpong, Virote ^e   Thongprasert, Sumitra ^f   Chua, Daniel Tt ^c   Moore, Nicola ^k   Manegold, Christian ^l  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HKSAR Government   (Hong Kong)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d MAHIDOL UNIVERSITY   (Thailand)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f Faculty of Medicine Chiang Mai University   (Thailand)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

^l UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Antineoplastic combined chemotherapy protocol; Asian continental ancestry group; Bevacizumab; Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PLACEBO;

ADULT; ADVANCED CANCER; ARTICLE; ASIAN; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 79956133688     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01397.x     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyons, 2008.
2. SEER cancer statistics review 1975-2007. National Cancer Institute 2011 [Cited 3 Jan 2011]. Available from: .
3. Hattori M, Fujita M, Ito Y, Ioka A, Katanoda K, Nakamura Y. Use of a population-based cancer registry to calculate twenty-year trends in cancer incidence and mortality in Fukui Prefecture. J Epidemiol 2010; 20: 244-52.
4. Pham TM, Fujino Y, Ide R etal. Years of life lost due to cancer in a cohort study in Japan. Eur J Public Health 2009; 19: 189-92.
5. Lim GH, Wong CS, Chow KY, Bhalla V, Chia KS. Trends in long-term cancer survival in Singapore: 1968-2002. Ann Acad Med Singapore 2009; 38: 99-105.
6. Gridelli C, Maione P, Rossi A, De MF. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist 2007; 12: 1183-93.
7. Wu YL, Zhou Q. Lung cancer management in the Asia-Pacific region: what's the difference compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference. J Thorac Oncol 2007; 2: 574-6.
8. Vincent MD. Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 2009; 16: 9-21.
9. Pfister DG, Johnson DH, Azzoli CG etal. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-53.
10. Yin YM, Geng YT, Shao YF etal. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. J Exp Clin Cancer Res 2010; 29: 126.
11. NCCN Asia Consensus Panel. NCCN clinical practice guidelines in oncology - Asia consensus statement: non-small cell lung cancer V.1.2009. National Comprehensive Cancer Network 2009 [Cited 11 Feb 2011]. Available from: .
12. NCCN-Korea Non-Small Cell Lung Cancer Panel. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Korean guidelines V.2.2008. National Comprehensive Cancer Network 2008 [Cited 11 Feb 2011]. Available from: .
13. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931-4.
14. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005; 10: 382-91.
15. Hurwitz H, Fehrenbacher L, Novotny W etal. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
16. Sandler A, Gray R, Perry MC etal. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
17. Sandler A, Yi J, Hambleton J, Kolb MM, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) Study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC): International Association for the Study of Lung Cancer (IASLC). Chicago Multidisciplinary Symposium in Throracic Onology Chicago, IL; 13-15 November, 2008.
18. Reck M, von Pawel J, Zatloukal P etal. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
19. Crino L, Dansin E, Garrido P etal. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733-40.
20. Ichinose Y, Seto T, Kunitoh H etal. Clinical outcomes of bevacizumab in combination with paclitaxel/carboplatin compared with paclitaxel/carboplatin alone in previously untreated Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ESMO Annual Conference; 2009.
21. Reck M, von PJ, Zatloukal P etal. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-9.
22. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
23. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176-86.
24. Kawaguchi T, Matsumura A, Fukai S etal. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010; 5: 1001-10.
25. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009; 4: 1083-93.
26. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009; 39: 137-50.
27. Shepherd FA, Rodrigues PJ, Ciuleanu T etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
28. Hanna N, Shepherd FA, Fossella FV etal. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
29. Park JO, Kim SW, Ahn JS etal. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5233-9.
30. Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009; 15: 386-94.